Stock 1ZL ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Zai Lab Limited BOERSE MUENCHEN

Equities

1ZL

US98887Q1040

Market Closed - BOERSE MUENCHEN
Other stock markets
 15:43:02 2024-07-05 EDT 		5-day change 1st Jan Change
15.9 EUR +1.27% Intraday chart for Zai Lab Limited -4.85% -35.66%
06-27 Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing MT
06-20 Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing
MT
Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath
PU
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme
MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading
MT
Transcript : Zai Lab Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024
CI
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
BU
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise
MT
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
BU
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
CI
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
AQ
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug
MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
MT
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
BU
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
MT
Zai Lab Announces Participation in May and June Investor Conferences
BU
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. 1ZL Stock
  5. News Zai Lab Limited